Yuanwei Zang

520 citations
21 papers · 375 indexed · h-index 12
Topics
RNA modifications and cancer (3 papers)Cancer Mechanisms and Therapy (2 papers)Renal cell carcinoma treatment (2 papers)
Partner nations
ChinaUnited States

In The Last Decade

Yuanwei Zang

19 papers receiving 370 citations

Peers

Yuanwei Zang
Comparison fields: 5 of 67
  • Molecular Biology 197
  • Cancer Research 115
  • Pulmonary and Respiratory Medicine 71
  • Oncology 70
  • Pathology and Forensic Medicine 49
Replace Shulin Wu with:
Shulin Wu China
Tetsuhiro Horie Japan
Yanghe Zhang China
Jiming Bao China
Jeanine Traag United States
Samina Dongol China
Shangha Pan China
Mai Kanai Japan
Qingfei Meng China
Lawrence N. Barrera United Kingdom
Yuanwei Zang relative to Shulin Wu China Shulin Wu's profile →
Citations per field
00.5×2.9×
Shulin Wu · 1×
Citations per year

Countries citing papers authored by Yuanwei Zang

Since Specialization
Citations

This map shows the geographic impact of Yuanwei Zang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuanwei Zang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuanwei Zang more than expected).

Fields of papers citing papers by Yuanwei Zang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuanwei Zang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuanwei Zang. The network helps show where Yuanwei Zang may publish in the future.

Co-authorship network of co-authors of Yuanwei Zang

This figure shows the co-authorship network connecting the top 25 collaborators of Yuanwei Zang. A scholar is included among the top collaborators of Yuanwei Zang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuanwei Zang. Yuanwei Zang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 3
2 0
3 0
4 2
5 9
6 38
7 25
8 5
9 45
10 16
11 22
12 9
13 30
14
Inhibition of HIF-1α by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo.
43
15 6
16 1
17 21
18 14
19 30
20 20

About Yuanwei Zang

Yuanwei Zang is a scholar working on Cancer Research, Energy Engineering and Power Technology and Biochemistry, having authored 21 papers that have together received 375 indexed citations. Recurring topics across this work include RNA modifications and cancer (3 papers), Cancer Mechanisms and Therapy (2 papers) and Renal cell carcinoma treatment (2 papers). The work is most often cited by research in Cancer Research (115 citations), Biochemistry (43 citations) and Molecular Biology (197 citations). Yuanwei Zang has collaborated with scholars based in China and United States. Frequent co-authors include Zhonghua Xu, Liang Fang, Juchao Ren, Yongzhen Zhang, Yong‐Zhen Zhang, Liang Qiao, Wenjun Ni, Jingxin Li, Zeyan Li and Yongxiang Li. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Cell Biology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026